**PROJECT NARRATIVE**

In contrast to the current questionnaire based screening tools for autism spectrum disorders (ASD) that suffer from vast amounts of false positives, and a host of demographic, socio-economic and interpretative biases, we aim to validate an automated tool that estimates ASD risk by analyzing patterns of co-morbidities in individual patient medical histories, at no additional administrative burden or resource utilization. The ASD Co-morbid Risk (ACoR) methodology has superior performance to M-CHAT/F in preliminary studies. Further, on account of functional independence the two scores may be combined to further boost performance to either boost positive predictive value upto 100% or sensitivity upto 50% with no loss in current specificity.